Since its founding, Tufts CSDD has been a leader in conducting objective and scholarly studies quantifying critical economic and performance variables characteriazing the drug development enterprise over extended periods of time. Conducted every three to five years, the results of these studies and their insights are referenced and quoted extensively and have informed and influenced regulators, policy makers, academics, and drug development professionals worldwide. Our longitudinal studies are funded by unrestricted research grants. Contact Tufts CSDD to learn more about any of our longitudinal studies.
Dr. Joseph DiMasi’s pioneering studies on the cost of drug development provide an excellent example of the compelling results and insights from our longitudinal studies and demonstrate their ability to engage the drug development community in substantive and valuable dialogue. Learn more about our 2016 Cost Study.
Seminal longitudinal studies include: